Table 2.
AUROC by subgroup analysis.
| Subgroup | Test data set, AUROC (95% CI) | Validation data set, AUROC (95% CI) | |||||
|
|
|
Disease progression | Cancer-specific mortality | All-cause mortality | Disease progression | Cancer-specific mortality | All-cause mortality |
| Age at diagnosis |
|
|
|
|
|
|
|
|
|
<45 years | 0.79 (0.74-0.85) | 0.79 (0.71-0.87) | 0.83 (0.77-0.89) | 0.80 (0.73-0.88) | 0.91 (0.81-1.00) | 0.94 (0.88-1.00) |
|
|
45-54 years | 0.80 (0.74-0.86) | 0.79 (0.71-0.88) | 0.81 (0.74-0.89) | 0.79 (0.70-0.88) | 0.84 (0.72-0.96) | 0.85 (0.73-0.98) |
|
|
55-64 years | 0.75 (0.67-0.83) | 0.80 (0.72-0.88) | 0.82 (0.75-0.90) | 0.77 (0.63-0.90) | 0.80 (0.59-1.00) | 0.83 (0.64-1.00) |
|
|
>64 years | 0.79 (0.67-0.92) | 0.82 (0.66-0.97) | 0.84 (0.74-0.93) | 0.79 (0.65-0.94) | 0.80 (0.60-1.00) | 0.85 (0.73-0.98) |
| Residence |
|
|
|
|
|
|
|
|
|
Urban | 0.78 (0.73-0.82) | 0.80 (0.75-0.86) | 0.82 (0.78-0.86) | 0.78 (0.74-0.84) | 0.84 (0.75-0.93) | 0.90 (0.85-0.96) |
|
|
Rural | 0.81 (0.75-0.87) | 0.77 (0.67-0.87) | 0.84 (0.77-0.91) | 0.80 (0.71-0.90) | 0.84 (0.71-0.97) | 0.84 (0.70-0.98) |
| Receptor type |
|
|
|
|
|
|
|
|
|
ERa–/PRb–/HER2c– | 0.69 (0.61-0.78) | 0.63 (0.52-0.74) | 0.70 (0.60-0.79) | 0.92 (0.83-1.00) | 0.96 (0.92-1.00) | 0.97 (0.94-1.00) |
|
|
ER–/PR–/HER2+ | 0.75 (0.63-0.87) | 0.86 (0.77-0.96) | 0.85 (0.76-0.94) | 0.70 (0.53-0.86) | 0.87 (0.62-1.00) | 0.87 (0.61-1.00) |
|
|
HRd+/HER2- | 0.84 (0.79-0.89) | 0.84 (0.78-0.91) | 0.87 (0.82-0.92) | 0.73 (0.63-0.83) | 0.75 (0.59-0.92) | 0.83 (0.70-0.97) |
|
|
HR+/HER2+ | 0.69 (0.55-0.82) | 0.69 (0.48-0.89) | 0.78 (0.63-0.94) | 0.87 (0.81-0.94) | 0.81 (0.65-0.97) | 0.84 (0.70-0.97) |
aER: estrogen receptor.
bPR: progesterone receptor.
cHER2: human epidermal growth factor receptor.
dHR: hormone receptor.